NovoCure Limited filed a Form S-8 registration statement with the U.S. Securities and Exchange Commission on October 29, 2026, to register an additional 13,133,749 ordinary shares issuable under its Amended and Restated 2024 Omnibus Incentive Plan.

Key Highlights

  • Shares registered: 13,133,749 additional ordinary shares are being registered under the NovoCure Limited Amended and Restated 2024 Omnibus Incentive Plan.
  • Shareholder-approved expansion: 9,000,000 of those shares reflect an amendment and restatement of the 2024 Plan approved by the company's shareholders on June 3, 2026.
  • Recycled shares: The remaining 4,133,749 shares are ordinary shares from the 2024 Plan and the NovoCure Limited 2015 Omnibus Incentive Plan that will become available for re-grant under the 2024 Plan's share recycling provisions.
  • Filer classification: NovoCure Limited is identified in the filing as a large accelerated filer.
  • Signing officer: Chief Financial Officer Christoph Brackmann signed the registration statement on behalf of the registrant on October 29, 2026, in the City of Baar, Switzerland.
  • Prior registrations: The filing incorporates by reference ten previous Form S-8 registration statements filed between March 1, 2016 and February 26, 2026.

NovoCure Expands 2024 Omnibus Incentive Plan Share Pool

According to the filing, NovoCure Limited submitted this Form S-8 to register 13,133,749 additional ordinary shares that may be issued under the NovoCure Limited Amended and Restated 2024 Omnibus Incentive Plan. The registrant disclosed that the total consists of two components: 9,000,000 ordinary shares added to the 2024 Plan pursuant to an amendment and restatement approved by shareholders on June 3, 2026, and 4,133,749 ordinary shares from both the 2024 Plan and the NovoCure Limited 2015 Omnibus Incentive Plan that will become available for re-grant in accordance with the share recycling provisions of the 2024 Plan.

The filing notes that NovoCure is incorporated in Jersey and maintains its principal executive offices at No. 4 The Forum, Grenville Street, St. Helier, Jersey JE2 4UF. The agent for service listed is Christoph Brackmann, Chief Financial Officer, at an address in Wayne, Pennsylvania. The registrant incorporated by reference its Annual Report on Form 10-K for the year ended December 31, 2025, Quarterly Reports on Form 10-Q for the quarters ended March 31, June 30, and September 30, 2026, and several Current Reports on Form 8-K filed between April 9, 2026 and September 9, 2026.

The registration statement also incorporates by reference the contents of ten prior Form S-8 filings, identified by file numbers 333-209854 through 333-293770, filed between March 1, 2016 and February 26, 2026, each of which covered ordinary shares issuable under the 2024 Plan or its predecessors. The filing was signed on October 29, 2026, by CEO Frank Leonard, CFO Christoph Brackmann, Executive Chairman William F. Doyle, and multiple directors.

What Was Disclosed

NovoCure Limited filed a Form S-8 on October 29, 2026, registering 13,133,749 additional ordinary shares under its Amended and Restated 2024 Omnibus Incentive Plan, comprising 9,000,000 shareholder-approved new shares and 4,133,749 shares available for re-grant through recycling provisions.